Literature DB >> 23354675

Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.

E Montassier1, E Batard, T Gastinne, G Potel, M F de La Cochetière.   

Abstract

Bacteremia remains a major cause of life-threatening complication in patients with cancer. Significant changes in the spectrum of microorganisms isolated from blood culture have been reported in cancer patients over the past years. The aim of our systematic review was to inventory the recent trends in epidemiology and antibiotic resistance of microorganisms causing bacteremia in cancer patients. Data for this review was identified by searches of Medline, Scopus and Cochrane Library for indexed articles and abstracts published in English since 2008. The principal search terms were: "antimicrobial resistance", "bacteremia", "bacterial epidemiology", "bloodstream infection", "cancer patients", "carbapenem resistance", "Escherichia coli resistance", "extended-spectrum β-lactamase producing E. coli", "febrile neutropenia", "fluoroquinolone resistance", "neutropenic cancer patient", "vancomycin-resistant Enterococcus", and "multidrug resistance". Boolean operators (NOT, AND, OR) were also used in succession to narrow and widen the search. Altogether, 27 articles were selected to be analyzed in the review. We found that Gram-negative bacteria were the most frequent pathogen isolated, particularly in studies with minimal use of antibiotic prophylaxis. Another important trend is the extensive emergence of antimicrobial-resistant strains associated with increased risk of morbidity, mortality and cost. This increasing incidence of antibiotic resistance has been reported in Gram-negative bacteria as well as in Gram-positive bacteria. This exhaustive review, reporting the recent findings in epidemiology and antibiotic resistance of bacteremia in cancer patients, highlights the necessity of local continuous surveillance of bacteremia and stringent enforcement of antibiotic stewardship programs in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354675     DOI: 10.1007/s10096-013-1819-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  56 in total

Review 1.  Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.

Authors:  Eric James Bow
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

2.  High incidence of methicillin-resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital.

Authors:  S Quilty; G Kwok; K Hajkowicz; B Currie
Journal:  Intern Med J       Date:  2009-08       Impact factor: 2.048

3.  The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

Authors:  Mini Kamboj; Dick Chung; Susan K Seo; Eric G Pamer; Kent A Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-26       Impact factor: 5.742

Review 4.  Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.

Authors:  S H Zinner
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

5.  Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation.

Authors:  D Kapur; D Dorsky; J M Feingold; R D Bona; R L Edwards; J Aslanzadeh; P J Tutschka; S Bilgrami
Journal:  Bone Marrow Transplant       Date:  2000-01       Impact factor: 5.483

6.  Management of fever in neutropenic patients with different risks of complications.

Authors:  Jean Klastersky
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

7.  Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.

Authors:  Enrico M Trecarichi; Mario Tumbarello; Teresa Spanu; Morena Caira; Luana Fianchi; Patrizia Chiusolo; Giovanni Fadda; Giuseppe Leone; Roberto Cauda; Livio Pagano
Journal:  J Infect       Date:  2009-03-09       Impact factor: 6.072

8.  Bacterial isolates in neutropenic febrile patients.

Authors:  M Karim; W Khan; B Farooqi; I Malik
Journal:  J Pak Med Assoc       Date:  1991-02       Impact factor: 0.781

9.  Bacterial infection profiles in lung cancer patients with febrile neutropenia.

Authors:  Jean-Philippe Lanoix; Emilie Pluquet; Francois Xavier Lescure; Houcine Bentayeb; Emmanuelle Lecuyer; Marie Boutemy; Patrick Dumont; Vincent Jounieaux; Jean Luc Schmit; Charles Dayen; Youcef Douadi
Journal:  BMC Infect Dis       Date:  2011-06-27       Impact factor: 3.090

10.  Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study.

Authors:  Seema Irfan; Faiza Idrees; Vikram Mehraj; Faizah Habib; Salman Adil; Rumina Hasan
Journal:  BMC Infect Dis       Date:  2008-06-09       Impact factor: 3.090

View more
  80 in total

1.  Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Authors:  Katsuhiro Miura; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Masashi Sakagami; Shimon Ohtake; Sumiko Kobayashi; Atsuko Hojo; Daisuke Kurita; Yujin Kobayashi; Machiko Kusuda; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
Journal:  Int J Hematol       Date:  2015-12-29       Impact factor: 2.490

Review 2.  The dormant blood microbiome in chronic, inflammatory diseases.

Authors:  Marnie Potgieter; Janette Bester; Douglas B Kell; Etheresia Pretorius
Journal:  FEMS Microbiol Rev       Date:  2015-05-03       Impact factor: 16.408

3.  Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network.

Authors:  Jordi Rello; Cristina Sarda; Djamel Mokart; Kostoula Arvaniti; Murat Akova; Alexis Tabah; Elie Azoulay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-09       Impact factor: 3.267

4.  16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation.

Authors:  Emmanuel Montassier; Eric Batard; Sébastien Massart; Thomas Gastinne; Thomas Carton; Jocelyne Caillon; Sophie Le Fresne; Nathalie Caroff; Jean Benoit Hardouin; Philippe Moreau; Gilles Potel; Françoise Le Vacon; Marie France de La Cochetière
Journal:  Microb Ecol       Date:  2014-01-09       Impact factor: 4.552

5.  Does a learned journal require regular re-vamping?

Authors:  A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08       Impact factor: 3.267

Review 6.  Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.

Authors:  Xiao Jun Wang; Alexandre Chan
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

7.  Ertapenem usage in cancer patients with and without neutropenia: a report on 97 cases from a comprehensive cancer center.

Authors:  L Nesher; F P Tverdek; S N Mahajan; R F Chemaly; Kenneth V I Rolston
Journal:  Infection       Date:  2015-05-01       Impact factor: 3.553

8.  Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers.

Authors:  Hsiang-Fong Kao; I-Chun Chen; Chiun Hsu; Sin-Yuan Chang; Shu-Fen Chien; Yee-Chun Chen; Fu-Chang Hu; James Chih-Hsin Yang; Ann-Lii Cheng; Kun-Huei Yeh
Journal:  Support Care Cancer       Date:  2014-01-03       Impact factor: 3.603

Review 9.  Bloodstream infections in patients with solid tumors.

Authors:  Carlota Gudiol; José María Aguado; Jordi Carratalà
Journal:  Virulence       Date:  2016-01-19       Impact factor: 5.882

10.  Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.

Authors:  Rodrigo E Mendes; Helio S Sader; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.